share_log

Tracon Pharmaceuticals | S-8 POS: S-8 POS

Tracon Pharmaceuticals | S-8 POS: S-8 POS

Tracon Pharmaceuticals | S-8 POS：员工福利计划证券登记(修正)
美股SEC公告 ·  10/31 16:23

Moomoo AI 已提取核心信息

Tracon Pharmaceuticals, Inc., a biopharmaceutical company, has filed Post-Effective Amendment No. 1 to deregister securities under multiple Form S-8 Registration Statements with the U.S. Securities and Exchange Commission (SEC) on October 31, 2024. The amendments affect registration statements dating from January 30, 2015, to March 7, 2024, which had registered shares of common stock related to the company's equity incentive and employee stock purchase plans. The deregistration follows the board of directors' approval of the company's dissolution and liquidation, as disclosed in a Form 8-K filed on July 30, 2024, pending stockholder approval. The company has terminated the offerings of securities under these registration statements and removed any unsold securities as part of the liquidation process. The filings were signed by Craig R. Jalbert, President and Chief Executive Officer of Tracon Pharmaceuticals.
Tracon Pharmaceuticals, Inc., a biopharmaceutical company, has filed Post-Effective Amendment No. 1 to deregister securities under multiple Form S-8 Registration Statements with the U.S. Securities and Exchange Commission (SEC) on October 31, 2024. The amendments affect registration statements dating from January 30, 2015, to March 7, 2024, which had registered shares of common stock related to the company's equity incentive and employee stock purchase plans. The deregistration follows the board of directors' approval of the company's dissolution and liquidation, as disclosed in a Form 8-K filed on July 30, 2024, pending stockholder approval. The company has terminated the offerings of securities under these registration statements and removed any unsold securities as part of the liquidation process. The filings were signed by Craig R. Jalbert, President and Chief Executive Officer of Tracon Pharmaceuticals.
tracon pharmaceuticals公司，一家生物制药公司，于2024年10月31日向美国证券交易委员会（SEC）提交了关于多个S-8表格注册声明的Post生效修正案件第1号。这些修正案涉及自2015年1月30日至2024年3月7日期间的注册声明，这些声明注册了与公司股权激励和员工股票购买计划相关的普通股股份。该注销是在董事会批准公司解散和清算的情况下完成的，这一情况在2024年7月30日提交的8-k表格中披露，待股东批准。公司已经终止了这些注册声明下的证券发行，并在清算过程中移除了任何未售出的证券。这些文件由tracon pharmaceuticals的总裁兼首席执行官Craig R. Jalbert签署。
tracon pharmaceuticals公司，一家生物制药公司，于2024年10月31日向美国证券交易委员会（SEC）提交了关于多个S-8表格注册声明的Post生效修正案件第1号。这些修正案涉及自2015年1月30日至2024年3月7日期间的注册声明，这些声明注册了与公司股权激励和员工股票购买计划相关的普通股股份。该注销是在董事会批准公司解散和清算的情况下完成的，这一情况在2024年7月30日提交的8-k表格中披露，待股东批准。公司已经终止了这些注册声明下的证券发行，并在清算过程中移除了任何未售出的证券。这些文件由tracon pharmaceuticals的总裁兼首席执行官Craig R. Jalbert签署。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间